SK Bioscience announced on the 11th that it had received approval from Thailand’s Central Research Ethics Committee (CREC) for a phase 3 clinical trial plan to confirm the booster shot effect of GBP510, the ‘first Korean’ COVID-19 vaccine.
In phase 3 clinical trials, immunogenicity and safety will be assessed by administering GBP510 as a third booster shot to 450 adults aged 18 years or older who have received two doses of GBP510 or AstraZeneca’s novel coronavirus infection (COVID-19) vaccine.
SK Bioscience said, “GBP510 is a recombinant protein nanoparticle vaccine,” and is expected to be sufficiently safe while improving the immune response that decreases over time after primary vaccination through booster shots.”
In Korea, GBO510 received product approval from the Ministry of Food and Drug Safety on the 29th of last month.
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asia Innovation Hub Pangyo Techno Valley 2022’ news